Heart rhythm breakthrough: drug and lifestyle combo targets AF
NCT ID NCT03603912
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 22 times
Summary
This study tests whether the diabetes drug metformin, combined with lifestyle and risk factor changes, can reduce episodes of atrial fibrillation (AF) in people with pacemakers or defibrillators. About 175 participants with recent AF episodes will be randomly assigned to receive metformin or placebo, plus lifestyle coaching or standard care. The goal is to see if these approaches lower the daily time spent in AF over one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
Conditions
Explore the condition pages connected to this study.